African Tick Bite Fever

African Tick Bite Fever (ATBF) is a bacterial infection caused by the bite of an infected tick. It was first discovered in 1930, however it was not until 1992 that the agent of the disease, the Rickettsia africae bacterium, was isolated. It is estimated that approximately 4-5% of European travelers returning from sub-Saharan Africa and the West Indies, the regions where ATBF is endemic, become infected with ATBF.

Those travelling to the regions of sub-Saharan Africa and the West Indies are at greatest risk of contracting ATBF. Although all persons are susceptible, travellers engaging in outdoor activities in these regions (camping, farming, hiking, hunting, visiting game reserves, etc.) will be at higher risk of infection.

ATBF occurs most commonly from November to April when the ticks carrying the disease are most active.

Symptoms of ATBF include fever, headache, muscle pain and soreness, chills and a rash. The site of the bite(s) may be sore and red in colour with a dark, scabby center. Some people may have no symptoms of infection.

The symptoms of ATBF may appear quite similar to the symptoms of Mediterranean Spotted Fever, however they are typically milder.

Rare symptoms such as inflammation of the lymph nodes, brain and heart have also been reported.

The patient should seek medical attention when they suspect that they have been in contact with a tick, find a tick on their body or as soon as symptoms appear.

Doxycycline is the recommended antibiotic for the treatment of ATBF and should be the first treatment given to patients suspected to have contracted ATBF. With doxycycline treatment, symptom relief should be noted within 48 hours. Generally, doxycycline treatment lasts 5-10 days. Tetracycline treatment may also be recommended by medical professionals.

ATBF is endemic in sub-Saharan Africa and the West Indies particularly in rural areas where infected ticks, and the animals on which they live, are more widespread.